Advertisement

α-Asarone: a hypnotic with a potential for long-term use

  • Arathi Radhakrishnan
  • N. Jayakumari
  • Velayudhan Mohan Kumar
  • Kamalesh K. Gulia
Original Article

Abstract

Commonly used hypnotics are not very effective for the management of chronic insomnia as they produce several unpleasant side effects. According to a recent report, short-term administration of 10 mg/kg α-Asarone, an active principle of Acorus species, used in traditional Indian and Chinese medicine for a prolonged period without any ill-effects, promoted sleep in rats. However, the efficacy of α-Asarone in promoting sleep on long-term use has not been studied. Study was conducted on four groups of rats, with electrodes implanted for recording sleep. Thermocouple and radio-transmitter were implanted for recording temperatures from hypothalamus and peritoneum. Of these, three groups of rats were sleep deprived for 5 h (9:00–14:00 h) for 21 days after drug (α-Asarone or midozolam) or vehicle administration. The anxiety levels were also studied in these rats. Another group, that received α-Asarone for 21 days, was not subjected to sleep deprivation. Long-term administration of α-Asarone improved both the quantity and quality of NREM sleep, not only in comparison to the vehicle, but also in contrast to midazolam. Moreover, there was no withdrawal effect after stopping the daily administration of α-Asarone for 3 weeks. Anxiety alleviation produced by α-Asarone was better than midazolam. α-Asarone-mediated anxiolysis, mild hypothermia, and NREM sleep-related alterations in temperatures, and its known antioxidant property, might have contributed towards the improvement in NREM sleep and maintenance of REM sleep. The study provides strong pre-clinical evidences for further research on α-Asarone as a possible treatment option for chronic insomnia.

Keywords

α-Asarone Hypnotic Chronic Sleep deprivation Sleep quality Anxiolytic 

Abbreviations

S–W

Sleep–wakefulness

Thy

Hypothalamic temperature

Tbody

Body temperature

SD

Sleep deprivation

NREM

Non-rapid eye movement

REM

Rapid eye movement

Notes

Acknowledgements

The work was supported by the research grant from the Council of Scientific and Industrial Research, New Delhi, India (CSIR Sanction No: 37(1543)/12-EMR II). AR was supported by CSIR Junior Research Fellowship.

Compliance with ethical standards

Conflict of interest

None of the authors has any financial interest or conflicts of interest related to this work.

Ethical approval

All the surgeries and procedures employed in this study were approved by the Institutional Animal Ethics Committee of the Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala (SCT/TAEC-019/June/2012/77).

Animals

Wistar rats were obtained from the Division of Laboratory Animal Sciences, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala.

References

  1. 1.
    Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111.CrossRefGoogle Scholar
  2. 2.
    Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262:1479–84.CrossRefGoogle Scholar
  3. 3.
    Shapiro CM, Devins GM, Hussain M. ABC of sleep disorders. Sleep problems in patients with medical illness. BMJ. 1993;306:1532.CrossRefGoogle Scholar
  4. 4.
    Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007;30:213.CrossRefGoogle Scholar
  5. 5.
    Vgontzas AN, Kales A. Sleep and its disorders. Annu Rev Med. 1999;50:387–400.CrossRefGoogle Scholar
  6. 6.
    Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11.CrossRefGoogle Scholar
  7. 7.
    Ashton H. Guidelines for the rational use of benzodiazepines. Drugs. 1994;48:25–40.CrossRefGoogle Scholar
  8. 8.
    Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65:7–12.Google Scholar
  9. 9.
    Stone JR, Zorick TS, Tsuang J. Dose-related illusions and hallucinations with zaleplon. Clin Toxicol. 2008;46:344–5.CrossRefGoogle Scholar
  10. 10.
    Herings RM, Stricker BHC, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med. 1995;155:1801–7.CrossRefGoogle Scholar
  11. 11.
    Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry. 1993;163:386–93.CrossRefGoogle Scholar
  12. 12.
    Alvaro PK, Roberts RM, Harris JK. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep. 2013;36(7):1059–68.CrossRefGoogle Scholar
  13. 13.
    Taylor DJ, Lichstein KL, Durrence HH, et al. Epidemiology of insomnia, depression, and anxiety. Sleep. 2005;28(11):1457–64.CrossRefGoogle Scholar
  14. 14.
    Gulia KK, Radhakrishnan A, Kumar VM. Approach to sleep disorders in the traditional school of Indian medicine. Complementary and alternative medicine. In: Chokroverty S, editor. Sleep disorders medicine part 2, 4th ed. New York: Springer Science + Business Media, LLC; 2017.Google Scholar
  15. 15.
    Kumar VM, Gulia KK. Sleep medicine in Ayurveda. Sleep Med Rev. 2016;25:131.CrossRefGoogle Scholar
  16. 16.
    Radhakrishnan A, Jayakumari N, Kumar VM, et al. Sleep promoting potential of low dose α-Asarone in rat model. Neuropharmacology. 2017;125:13–29.CrossRefGoogle Scholar
  17. 17.
    Radhakrishnan A, Jayakumari N, Kumar VM, et al. α-Asarone in management of sleep deprivation induced memory deficits and anxiety in rat model. Sleep Biol Rhythm. 2018.  https://doi.org/10.1007/s41105-018-0181-7 CrossRefGoogle Scholar
  18. 18.
    Paxino G, Watson C. The rat brain in stereotaxic coordinates. 3rd ed. San Diego: Academic Press, Inc.; 1997.Google Scholar
  19. 19.
    Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. JCSM. 2008;4:487.PubMedGoogle Scholar
  20. 20.
    Michelini S, Cassano GB, Frare F, et al. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(4):127–34.CrossRefGoogle Scholar
  21. 21.
    Sanger DJ, Zivkovic B. Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology. 1987;26(10):1513–8.CrossRefGoogle Scholar
  22. 22.
    Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14(5):287–304.CrossRefGoogle Scholar
  23. 23.
    Buysse DJ. Chronic insomnia. Am J Psychiatry. 2008;165(6):678–86.CrossRefGoogle Scholar
  24. 24.
    Merica H, Blois R, Gaillard JM. Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci. 1998;10(5):1826–34.CrossRefGoogle Scholar
  25. 25.
    Aeschbach D, Dijk DJ, Trachel L, et al. Dynamics of slow wave activity and spindle frequency activity in the human sleep EEG: effect of midazolam and zopiclone. Neuropsychopharmacology. 1994;11:237–44.CrossRefGoogle Scholar
  26. 26.
    Bastian CH, LeBlanc M, Carrier J, et al. Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines. Sleep. 2003;26:313–7.CrossRefGoogle Scholar
  27. 27.
    Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. Psychopharmacology. 1996;126:1–16.CrossRefGoogle Scholar
  28. 28.
    Borbely AA, Achermann P. Ultradian dynamics of sleep after a single dose of benzodiazepine hypnotics. Eur J Pharmacol. 1991;195:11–8.CrossRefGoogle Scholar
  29. 29.
    Feige B, Voderholzer U, Riemann D, et al. Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects. Clin Neurophysiol. 1999;110:1965–74.CrossRefGoogle Scholar
  30. 30.
    Kales A, Scharf MB, Kales JD. Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA. 1979;241:1692–5.CrossRefGoogle Scholar
  31. 31.
    Deboer T, Franken P, Tobler L. Sleep and cortical temperature in the Djungarian hamster under baseline conditions and after sleep deprivation. J Comp Physiol. 1994;174:145–55.CrossRefGoogle Scholar
  32. 32.
    Parmeggiani PL, Velluti RA. The physiologic nature of sleep. World Sci. 2005;18:391.Google Scholar
  33. 33.
    Gilbert SS, van den Heuvel CJ, Ferguson SA, et al. Thermoregulation as a sleep signalling system. Sleep Med Rev. 2004;8:81–93.CrossRefGoogle Scholar
  34. 34.
    Amici R, Bastianini S, Berteotti C, et al. Sleep and bodily functions: the physiological interplay between body homeostasis and sleep homeostasis. Arch Ital Biol. 2014;152:66–78.PubMedGoogle Scholar
  35. 35.
    Mallick HN, Kumar VM. Basal forebrain thermoregulatory mechanism modulates auto-regulated sleep. Front Neurol. 2012;3:102.CrossRefGoogle Scholar
  36. 36.
    Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep. 2007;30(7):873–80.CrossRefGoogle Scholar
  37. 37.
    Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37(1):9–15.CrossRefGoogle Scholar
  38. 38.
    Anseloni VZ, Brandao ML. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze. Behav Pharmacol. 1997;8:533–40.CrossRefGoogle Scholar
  39. 39.
    Zangrossi H, Viana MB, Graeff FG. Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino) tetralin in the elevated T-maze. Eur J Pharmacol. 1999;369:267–70.CrossRefGoogle Scholar
  40. 40.
    Groenink L, Vinkers C, Oorschot R, et al. Models of anxiety: stress-induced hyperthermia (SIH) in singly housed mice. Curr Protoc Pharmacol. 2009;5:16.PubMedGoogle Scholar
  41. 41.
    Olivier B, Zethof T, Pattij T, et al. Stress-induced hyperthermia and anxiety: pharmacological validation. Eur J Pharmacol. 2003;463:117–32.CrossRefGoogle Scholar
  42. 42.
    Borbely AA, Neuhaus HU. Sleep-deprivation: effects on sleep and EEG in the rat. J Comp Physiol. 1979;133(1):71–87.CrossRefGoogle Scholar
  43. 43.
    Colavito V, Fabene PF, Grassi Zucconi G, et al. Experimental sleep deprivation as a tool to test memory deficits in rodents. Front Syst Neurosci. 2013;7:106.CrossRefGoogle Scholar
  44. 44.
    Shido O, Sugimoto N, Sakurada S, et al. Body core temperature of rats subjected to daily exercise limited to a fixed time. ‎Int J Biometeorol. 1997;40(3):135–40.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Sleep Research 2018

Authors and Affiliations

  1. 1.Division of Sleep Research, Biomedical Technology WingSree Chitra Tirunal Institute for Medical Sciences and TechnologyTrivandrumIndia
  2. 2.Department of BiochemistrySree Chitra Tirunal Institute for Medical Sciences and TechnologyTrivandrumIndia
  3. 3.Biomedical Technology WingSree Chitra Tirunal Institute for Medical Sciences and TechnologyTrivandrumIndia
  4. 4.TrivandrumIndia

Personalised recommendations